Nefecon新型不良事件的探索性分析
基于FAERS数据库对1515例IgA肾病患者使用Nefecon的不良事件进行不成比例分析,识别出5个阳性系统器官分类和23个阳性首选术语,其中乏力、不适、产品剂量遗漏问题和焦虑为新型不良事件,中位发病时间为31天,无高临床优先级事件。
要点
- Nefecon安全性良好,未发现高临床优先级事件。
- 识别出4个新型不良事件:乏力、不适、产品剂量遗漏问题、焦虑。
- 中位发病时间31天,所有WSP提示早期失败型特征。
核心结论
- Nefecon在IgA肾病患者中表现出良好的安全性,未识别出高临床优先级事件。
研究设计与样本
- 利用美国FDA不良事件报告系统(FAERS)的Nefecon上市后数据,采用不成比例分析(DPA)检测系统器官分类(SOC)和首选术语(PT)层面的阳性信号,共纳入1515例IgA肾病患者。
主要发现
- 识别出5个阳性SOC信号和23个阳性PT信号。
- 4个PT(乏力、不适、产品剂量遗漏问题、焦虑)为本研究新发现的不良事件。
- 无阳性PT被归类为高临床优先级,仅痤疮、高血压、面部肿胀和体重增加被视为中等临床优先级事件。
- 中位发病时间为31天,所有Weibull形状参数(WSP)检验结果均提示早期失败型特征。
临床怎么用
- 临床应关注Nefecon使用后31天左右可能出现的乏力、不适、产品剂量遗漏问题和焦虑等新型不良事件,并针对性别和年龄亚组的高相对风险事件进行早期警惕。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Nefecon, the first innovative drug approved by both the US Food and Drug Administration (FDA) and European Medicines Agency for IgA nephropathy (IgAN), lacked comprehensive real-world assessments of its adverse events (AEs). METHODS: We leveraged postmarketing data of Nefecon from the US FDA Adverse Event Reporting System (FAERS), employing disproportionate analysis (DPA) to detect positive signals at the system organ class (SOC) and preferred terms (PTs) levels. Duplicate AEs related to budesonide and those previously reported in studies were excluded through the use of the Medical Dictionary of Regulatory Activities (MedDRA). Our analysis encompassed time-to-onset (TTO), Weibull shape parameter (WSP) evaluation, cumulative incidence, clinical prioritization evaluation, and subgroup analysis based on gender and age. RESULTS: A total of 1515 individuals with IgAN were included. Five positive SOC signals and 23 positive PT signals were identified, including 4 PTs (asthenia, malaise, product dose omission issue, and anxiety) representing novel AEs newly identified in this study. None of the positive PTs were classified as high clinical priority, with only acne, hypertension, swelling face, and weight increased considered as moderate clinical priority events. The median time to TTO was 31 days. All WSP test results indicated an early failure type profile. Lastly, subgroup analysis provided further insights into the relative risk of specific AEs. CONCLUSION: Nefecon demonstrates a favorable safety profile, with no high-priority clinical events identified. The identification of novel AEs and subgroup-specific relative high-risk events fills a gap in existing studies and offers valuable insights for early clinical vigilance.
引用
- Wang J, Zhang Z, Liu X, et al. Exploring Novel Adverse Events of Nefecon. Kidney Int Rep. 2024. PMID: 39291217. doi:10.1016/j.ekir.2024.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。